Anti-chitinase-3-like protein-1 (YKL-40) neutralizing antibody and uses thereof
View Patent ↗Disclosed herein an isolated neutralizing antibody, which is capable of specifically binding to chitinase-3-like protein-1 (YKL-40) and uses thereof. The neutralizing antibody can further conjugate with a metal chelator to form an antibody complex. Further, labeling the antibody complex with a radioactive metal nuclide results in formation of a radioactive antibody complex, which can be used as a contrast agent and treatment for YKL-40 over-expression-related diseases. The radioactive antibody complex can specifically bind to YKL-40, and can be used for diagnosis and the preparation of the use of the treatment for cancers related to YKL-40 over-expression.
1 . An isolated neutralizing antibody that specifically binding to YKL-40, wherein the isolated neutralizing antibody comprising:
a heavy chain variable region (VH) comprising a CDR1 domain comprising the amino acid sequence of GYTFPNYGMN (SEQ ID NO: 1), a CDR2 domain comprising the amino acid sequence of WINTYTGEPTYTVDFKG (SEQ ID NO: 2), and a CDR3 domain comprising the amino acid sequence of ARSFYGTNGFDY (SEQ ID NO: 3); and
a light chain variable region (VL) comprising a CDR1 domain comprising the amino acid sequence of KASENVGTYVS (SEQ ID NO: 4), a CDR2 domain comprising the amino acid sequence of GASNRYI (SEQ ID NO: 5), and a CDR3 domain comprising the amino acid sequence of GQSYSYPPT (SEQ ID NO: 6).
2 . The isolated neutralizing antibody of claim 1 , wherein the heavy chain variable region (VH) comprises the amino acid sequence of SEQ ID NO: 7; and the light chain variable region (VL) comprises the amino acid sequence of SEQ ID NO: 8.
3 . A nucleic acid molecule encoding the isolated neutralizing antibody of claim 1 .
4 . A vector comprising the nucleic acid molecule of claim 3 .
5 . A host cell comprising the vector of claim 4 .
6 . An antibody complex, comprising the isolated neutralizing antibody of claim 1 conjugated with a metal chelating group, wherein the metal chelating group is 1,4,7-triazcyclononane-N,N′,N″-triacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7, 10-tetraacetic acid (DOTA), tetraazacyclododecane-1-ethyl, diethylenetriaminepentaacetic acid (DTPA), 1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N′″-tetraacetic acid (TETA), 1, 4,7-triazcyclononane phosphinic acid (TRAP) or ethylenediaminetetraacetic acid (EDTA).
7 . The antibody complex of claim 6 , wherein the metal chelating group is diethylenetriaminepentaacetic acid (DTPA).
8 . The antibody complex of claim 6 , further comprising a radioactive metal nuclide labeled on the antibody complex, wherein the radioactive metal nuclide is indium-111, lutetium-177, actinium-255, gallium-68, Gallium-67, Yttrium-90 or Copper-64.
9 . The antibody complex of claim 8 , wherein the radioactive metal nuclide is indium-111.
10 . The antibody complex of claim 8 , wherein the radioactive metal nuclide is lutetium-177.
11 . The antibody complex of claim 8 , wherein the radioactive metal nuclide is actinium-255.
12 . A contrast agent comprising the antibody complex of claim 8 and a contrast excipient.
13 . A pharmaceutical composition comprising the antibody complex of claim 8 .
14 . A method of treating a cancer overexpressing YKL-40, comprising administrating the antibody complex of claim 8 .
15 . The method of claim 14 , wherein the cancer is selected from the group consisting of: breast cancer, liver cancer, prostate cancer, brain cancer, astrocytoma, ovarian cancer, endometrial cancer, lung cancer, and gastrointestinal cancer.
16 . The method of claim 15 , wherein the cancer is epithelial ovarian cancer.
17 . A method of diagnosing a cancer overexpressing YKL-40, comprising administrating the antibody complex of claim 8 .
18 . The method of claim 17 , wherein the cancer is selected from the group consisting of: breast cancer, liver cancer, prostate cancer, brain cancer, astrocytoma, ovarian cancer, endometrial cancer, lung cancer, and gastrointestinal cancer.
19 . The method of claim 18 , wherein the cancer is epithelial ovarian cancer.